lncRNA qPCR challenges can arise from low transcript abundance, complex isoform structures and overlap with other genomic regions. These characteristics may affect assay specificity, amplification performance and the reliability of expression measurements.
Reliable RT-qPCR analysis of long non-coding RNAs depends on accurate transcript annotation, target-specific assay design, appropriate experimental controls and normalization strategies suited to the samples and study conditions.
Some long non-coding RNAs are expressed at low levels or in specific cell types, making reliable quantification more demanding than for many abundantly expressed protein-coding genes.
Incomplete or evolving transcript annotations can also complicate assay selection. When multiple isoforms share a target region, a qPCR assay may detect more than one transcript, depending on primer design and assay specificity.
Key analytical consideration: Define the intended transcript target before selecting a lncRNA qPCR assay. Evaluate primer specificity, amplification performance and normalization suitability for the samples and experimental conditions.
Low target abundance can produce variable Cq values or undetermined reactions, particularly when transcript levels approach the assay's detection or quantification limits.
How to address it: Evaluate assay sensitivity, detection and quantification limits, and replicate consistency. Optimize reaction conditions and consider targeted cDNA pre-amplification when appropriate.
Multiple lncRNA isoforms may share sequence regions, making it difficult to distinguish individual transcripts using a single qPCR assay.
How to address it: Review transcript structures and select target regions according to whether isoform-specific or combined expression measurement is required. Evaluate assay specificity for the intended transcripts.
Overlap with protein-coding genes or other transcribed regions can complicate target-specific amplification, particularly when sequences are shared.
How to address it: Assess primer specificity against overlapping transcripts and consider transcript orientation. Use no-reverse-transcription (no-RT) controls, when appropriate, to evaluate potential genomic DNA contamination.
Differences between annotation databases or transcript versions can lead to inconsistent target definitions and assay selection.
How to address it: Verify transcript identifiers, reference sequences and annotation versions before selecting or designing an assay.
Reference genes that vary across tissues, treatments or experimental groups can introduce bias into normalized expression measurements.
How to address it: Evaluate reference gene stability under the study conditions and select an appropriate normalization strategy. Consider multiple suitable reference genes when justified by the study design. Reliable expression comparisons also require sufficient biological replication to assess variability between samples.
FFPE-derived material, laser capture microdissection (LCM) samples or other limited-input specimens may yield insufficient or degraded RNA for consistent RT-qPCR measurements.
How to address it: Assess RNA quantity and quality, optimize reverse transcription and consider targeted cDNA pre-amplification only when compatible with the selected assays and sample characteristics.
Improving detection of low-expression lncRNAs starts with suitable assay sensitivity, sufficient input material and appropriate reverse transcription conditions. When target abundance is limited, the experimental workflow may require additional optimization.
For selected low-abundance targets or samples with limited RNA input, targeted cDNA pre-amplification may increase the amount of amplifiable material available for downstream qPCR. Its suitability depends on the target, assay compatibility and experimental workflow.
SpeAmp® supports targeted pre-amplification of selected cDNA sequences using appropriate primer pools before downstream qPCR analysis.
It may be considered for selected low-input workflows, including samples derived from FFPE tissue or laser capture microdissection (LCM), provided that suitable cDNA is available. Assay compatibility and performance should be assessed for the selected lncRNA targets.
Explore SpeAmp® pre-amplificationExperimental consideration: Targeted pre-amplification can introduce amplification bias between transcripts. Evaluate assay performance and maintain consistent pre-amplification conditions when comparing expression levels across samples. Pre-amplification cannot restore degraded RNA or compensate for inefficient reverse transcription.
AnyGenes® offers targeted lncRNA qPCR assays, flexible array formats, custom panels and technical guidance to support assay selection and experimental workflows adapted to specific research requirements.
Experimentally tested assays for selected lncRNA targets, with assay selection based on transcript identity, sequence characteristics and specificity requirements.
96- and 384-well formats for measuring multiple predefined lncRNA targets in structured expression studies across experimental conditions or sample groups.
Personalized panels assembled from selected lncRNA targets, with assay composition adapted to the biological model, target list and research objectives.
Primer selection or custom design informed by transcript annotation, isoform structure and genomic overlap, with specificity assessment for the intended lncRNA targets.
SpeAmp® targeted cDNA pre-amplification options for selected low-abundance lncRNAs or limited-input samples, depending on assay compatibility and sample characteristics.
Technical assistance with assay selection, experimental planning and evaluation of workflow suitability according to the lncRNA targets, sample characteristics and research objectives.
Some lncRNAs are expressed at low levels, have multiple transcript isoforms or overlap other transcribed regions. These characteristics can complicate assay design, target specificity and reliable expression measurement.
Reference genes should be evaluated for stable expression across the sample types and experimental conditions being studied. Using more than one suitable reference gene may improve normalization reliability.
Review transcript annotation, identify the intended isoform or shared target region, and evaluate primer specificity against related sequences. Experimental assay validation should confirm appropriate amplification specificity and efficiency under the intended conditions.
Sensitive assays, suitable reaction conditions and sufficient sample input can improve detection. Targeted cDNA pre-amplification, such as SpeAmp®, may be considered when appropriate. However, detection does not necessarily establish reliable quantification.
Standard qPCR design principles apply to lncRNAs, but assay suitability depends on the selected transcript. Isoform complexity, genomic overlap and low abundance may require additional specificity checks and experimental validation.
Yes. AnyGenes® can support lncRNA assay selection, custom qPCR panel configuration, transcript-aware primer design and consideration of low-input workflows according to project requirements.
Have specific lncRNA targets, assay requirements or challenging samples to investigate? Share your research needs with AnyGenes® to discuss suitable qPCR assays, custom panel configurations and targeted approaches adapted to your experimental conditions.
